Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- (Acyloxy) Alkyl (1)
- (HIV) infection (1)
- 1 (1)
- 2'3'-Dideoxynucleosides (1)
- 3'-Azido-2'3'-dideoxythymidine (AZT) (1)
-
- 4-Dihydro-1-methyl-3-[(pyridylcarbonyl)oxy]ester (1)
- 4-dihydro-1-methyl-3-pyridinylcarboxylic acid (1)
- 5'-O-Aliphatic derivatives of AZT (1)
- 5'-O-Ester prodrugs (1)
- 5'-O-Myristoyl derivatives of AZT (1)
- AZT Masked phosphate prodrugs (1)
- AZT monophosphate (1)
- Adamantane Conjugates (1)
- Amino acid ester (1)
- Aryl phosphate trimesters of AZT (1)
- Aspirin (O-acetylsalicylic acid) prodrug of AZT (1)
- Bicyclam-AZT Conjugates (1)
- Bis (S-Acyl-2-thioethyl) (SATE) esters of AZT-MP [ (1)
- Carbohydrate Derivatives (1)
- Carbohydrate Ester Derivatives (1)
- Carboxylic Esters (13-64) (1)
- Common cold (1)
- Cyclic 5'-O-carboxylic acids (1)
- Cyclosaligenyl-AZT (1)
- Diagnosis (1)
- Dialkyl phosphotriester derivatives (1)
- Diaryl phosphotriester derivatives (1)
- Dinucleoside phosphate derivatives (1)
- Diphosphate and triphosphate di (1)
- Ether Lipids (Els) (1)
Articles 1 - 2 of 2
Full-Text Articles in Diseases
The Common Cold: What Pharmacists Need To Know, Peggy Han, Peggy Mcmillan, Jeffery A. Goad
The Common Cold: What Pharmacists Need To Know, Peggy Han, Peggy Mcmillan, Jeffery A. Goad
Pharmacy Faculty Articles and Research
A primer on the common cold for pharmacists, including its causes and pathophysiology and how to assess and treat patients.
Novel Approaches For Designing 5'-O-Ester Prodrugs Of 3'-Azido-2'3'-Dideoxythymidine (Azt), Keykavous Parang, Leonard I. Wiebe, Edward E. Knaus
Novel Approaches For Designing 5'-O-Ester Prodrugs Of 3'-Azido-2'3'-Dideoxythymidine (Azt), Keykavous Parang, Leonard I. Wiebe, Edward E. Knaus
Pharmacy Faculty Articles and Research
3'-Azido-2'3'-dideoxythymidine (AZT, 1, zidovudine, RetrovirTM) is used to treat patients with human immunodeficiency virus (HIV) infection. AZT, after conversion to AZT-5'-triphosphate (AZT-TP) by cellular enzymes, inhibits HIV-reverse transcriptase (HIV-RT). The major clinical limitations of AZT are due to clinical toxicities that include bone marrow suppression, hepatic abnormalities and myopathy, absolute dependence on host cell kinase-mediated activation which leads to low activity, limited brain uptake, a sort half-life of about one hour in plasma that dictates frequent administration to maintain therapeutic drug levels, low potential for metabolic activation and/or high susceptibility to catabolism, and the rapid development of resistance by HIV-1. …